Litman Gregory Funds Trust Polen Capital Emerging Markets ex China Growth ETF (ARCA: PCEM)

Latest news for Litman Gregory Funds Trust Polen Capital Emerging Markets ex China Growth ETF (ARCA:PCEM)

 The Fund is a non-diversified, actively-managed exchange-traded fund (ETF) that seeks to achieve its objective by investing in a Because the Fund is non-diversified, it may invest a greater percentage of its assets in a particular investment or issuer than a diversified fund. Although the Fund may not concentrate (invest 25% or more of its net assets) in any industry, the Fund may focus its investments from time to time in one or more sectors of the economy or stock market. 

Polen Capital Emerging Markets ex-China Growth ETF

Litman Gregory Funds Trust Polen Capital Emerging Markets ex China Growth ETF

Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) will release earnings results for the fiscal fourth quarter, before the <a href="https://www.benzinga.com/quote/SPB/earnings">opening bell, on Friday, Nov. 15.</a>
The Middleton, Wisconsin-based company projects to report quarterly revenue of $747.51 million, compared to $740.7 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
On Aug. 8, Spectrum Brands reported better-than-expected third-quarter revenue results. Additionally, the company approved a $500 million share repurchase program.
With the recent buzz around Spectrum Brands ahead of quarterly earnings, some investors may be eyeing potential gains from the company's dividends, too. Spectrum Brands currently offers an annual dividend yield of 1.79%. That&#8217;s a quarterly dividend amount of 42 cents per share ($1.68 a year).
To figure out how to earn $500 monthly from Spectrum Brands, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Spectrum Brands' $1.68 dividend: $6,000 / $1.68 = 3,571 shares.
So, an investor would need to own approximately $334,603 worth of Spectrum Brands, or 3,571 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.68 = 714 shares, or $66,902 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
Price Action: Shares of Spectrum Brands fell by 1.1% to close at $93.70 on Wednesday. 
The company expects to report quarterly earnings at $1.07 per share. That&#8217;s down from $1.36 per share in the year-ago period. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41936916/top-4-consumer-stocks-that-may-explode-in-november">Top 4 Consumer Stocks That May Explode In November</a></li>
</ul>
Image: Shutterstock

Earnings

News

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From Spectrum Brands Stock Ahead Of Q4 Earnings

New Bank of America-led facility, with Delta Air Lines credit support, provides growth flexibility as Wheels Up expands its fleet with GrandView Aviation assets to enhance customer experience
ATLANTA, Nov. 14, 2024 /PRNewswire/ --&nbsp;On November 13, 2024, Wheels Up Experience Inc. (NYSE: <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4302797-1&amp;h=3033770264&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fwww.prnewswire.com%2Fnews-releases%2Fwheels-up-reports-third-quarter-results-302298188.html___.YXAzOndoZWVsc3VwOmE6bzo1MjZmMzZkMGZlMjk0MWU2M2VmODYyOTA1MmNlMWFmYTo2OjhmMjE6ZDU0OTRjOTE5MTBhNTg5MTM4OWY3ODgxNjFhNDZlZWY4YjQ3M2Q3Mzk0NDFjZmQ4Y2U4MzQxZWRlYWEyMWQ1ZjpwOkY6Tg%23financial-modal&amp;a=UP">UP</a>)&nbsp;closed its new $332&nbsp;million revolving equipment notes facility with Bank of America, and completed the acquisition of GrandView Aviation's fleet of 17 Embraer Phenom 300 and Phenom 300E aircraft, and related maintenance assets and customer programs. The closings mark a major step forward for Wheels Up's strategic growth goals, aimed at delivering an elevated and reliable experience for its customers. Wheels Up first announced that it had entered into definitive agreements for these transactions on October 22, 2024.

Financing

Wheels Up Secures $332M Revolving Financing Facility And Completes Acquisition Of 17 Phenom 300 Series Aircraft

As of Nov. 14, 2024, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">United States Lime &amp; Minerals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USLM#NASDAQ">USLM</a>)</h3>
<ul>
<li>On Oct. 30, United States Lime reported quarterly earnings of $1.16 per share, up from 73 cents per share in the year-ago period. &#8220;While our overall construction demand is down for the year-to-date, we did see improved demand from our construction customers in the third quarter 2024 as weather conditions in the South-Central United States returned to a more normal pattern compared to the heavier than usual rainfalls that we experienced in the first half 2024,&#8221; said Timothy W. Byrne, President and Chief Executive Officer. The company's stock gained around 41% over the past month and has a <a href="https://www.benzinga.com/quote/USLM">52-week high of $146.70</a>.</li>
<li>RSI Value: 83.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>USLM Price Action: Shares of United States Lime &amp; Minerals gained 3.5% to close at $142.58 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">ASP Isotopes Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>)</h3>
<ul>
<li>On Nov. 4, ASP Isotopes announced the closing of public offering and full exercise of underwriter&#8217;s option to purchase additional shares. The company's stock gained around 175% over the past month and <a href="https://www.benzinga.com/quote/ASPI">has a 52-week high</a> of $9.32.</li>
<li>RSI Value: 72.87</li>
<li>ASPI Price Action: Shares of ASP Isotopes gained 4.5% to close at $8.33 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Axalta Coating Systems Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>)</h3>
<ul>
<li>On Oct. 30, Axalta Coating Systems reported better-than-expected third-quarter adjusted EPS results and raised its FY24 adjusted EPS guidance. The company's stock gained around 10% over the past month and has a <a href="https://www.benzinga.com/quote/AXTA">52-week high</a> of $40.76.</li>
<li>RSI Value: 76.04</li>
<li>AXTA Price Action: Shares of Axalta Coating gained 2.5% to close at $40.60 on Wednesday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Short Ideas

Pre-Market Outlook

ASPI

AXTA

USLM

Top 3 Materials Stocks That Could Sink Your Portfolio This Month

Expanded CyPath&#xAE; Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states
Number of physician offices signed increased 75% over Q2 2024
Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54152730&amp;newsitemid=20241114473397&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=d08cc624d28f556ed758adfb50969d04">bioAffinity Technologies, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2024.
Key Highlights
<ul>
<li>Generated quarterly revenue of $2.4 million in the third quarter of 2024.</li>
<li>More than 1,300% growth rate for CyPath&#xAE; Lung orders in first nine months of 2024 over full-year 2023.</li>
<li>Number of physician offices signed increased by 75% compared to the second quarter of 2024, setting the stage for acceleration of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54152730&amp;newsitemid=20241114473397&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=629e0202d8368329c1a61ae23a3958ec">CyPath&#xAE; Lung</a> sales in the quarters ahead.</li>
<li>In October 2024, CyPath&#xAE; Lung was added to the U.S. Federal Supply Schedule (FSS), a procurement system that provides the Veterans Health Administration and the Military Health System streamlined access to state-of-the-art healthcare products and services. Under the FSS contract, Veterans at high risk for lung cancer will have easy access to CyPath&#xAE; Lung through 1,380 government health care facilities. Approximately 8,000 Veterans are treated for lung cancer annually, according to the VA.</li>
<li>Referrals and word-of-mouth from physicians, including key opinion leaders (KOLs), continues to be a key driver for expanding CyPath&#xAE; Lung in states beyond Texas; now receiving CyPath&#xAE; Lung orders from physicians in 11 states, up from eight in the second quarter of 2024. In addition to previously reported orders from Pennsylvania, New Jersey, North Carolina, Arizona, Michigan, California, and Ohio, physicians in Alabama, Louisiana and Illinois have also begun ordering CyPath&#xAE; Lung tests.</li>
<li>Added new sales representative to target increasing opportunities in Texas.</li>
<li>Continued to advance new product development initiatives in collaboration with Brooke Army Medical Center, the U.S Department of Defense's largest military health organization, focusing on tests that use the Company's artificial intelligence and flow cytometry platform for diagnosing COPD and a companion test with bronchoscopy.</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjheor.org%2Farticle%2F121512-economic-evaluation-of-a-novel-lung-cancer-diagnostic-in-a-population-of-patients-with-a-positive-low-dose-computed-tomography-result&amp;esheet=54152730&amp;newsitemid=20241114473397&amp;lan=en-US&amp;anchor=Economic+study&amp;index=3&amp;md5=fb6548535542dfb69003ec17abeb632e">Economic study</a> published in Journal of Health Economics and Outcomes Research, a peer-reviewed journal, concludes that adding CyPath&#xAE; Lung to the standard of care for Medicare patients with a positive lung cancer screening could have saved an average of $2,773 per patient for total cost savings of $379 million in 2022.</li>
<li>Awarded a Certificate of Grant of Patent from the Japan Patent Office for the Company's unique method using flow cytometry to predict the likelihood of lung disease, including the CyPath&#xAE; Lung diagnostic test for early-stage lung cancer.</li>
<li>Appointed William Bauta, Ph.D., as Chief Science Officer following the retirement of Vivienne I. Rebel, M.D., Ph.D. Dr. Bauta joined bioAffinity in 2016 as Senior Vice President. Previously, he was Associate Director of science at Genzyme.
<ul>
<li>Successfully closed a $2.7 million registered direct offering and concurrent private placement to fund continued growth.</li>
</ul>
</li>
</ul>

BIAF

bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States

Biotech

General

MBRX

Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial  Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects

ZENA

ZenaTech Q3 2024 Revenue $166,886, Up 15% YoY

Guidance

Management

Tech

ASML

ASML CEO Said AI-driven Shift Toward Advanced Logic And Memory Chips Benefits ASML

Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.36) per share from the same period last year.

Earnings Beats

RANI

Rani Therapeutics Hldgs Q3 EPS $(0.24) Beats $(0.27) Estimate

IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(1.41) by 70.92 percent.

IMCC

IM Cannabis Q3 2024 Adj EPS $(0.41) Beats $(1.41) Estimate

UBS analyst Michael Goldsmith downgrades Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) from Buy to Neutral and lowers the price target from $155 to $134.

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Sun Communities to Neutral, Lowers Price Target to $134

&nbsp;Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra&#x2122; following injection into an affected joint in patients with psoriatic arthritis. No safety concerns were recorded following the dosing of the first patient.
The trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for psoriatic arthritis. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and secondary endpoints will include assessments of change from baseline in pain and other parameters of disease activity for up to 12 months following administration of Allocetra&#x2122;.

ENLV

Enlivex Announces The Dosing Of The First Patient In A Phase I Clinical Trial  Evaluating The Safety, Tolerability And Potential Therapeutic Effect Of Allocetra In Patients With Psoriatic Arthritis

ASML CEO, AT Investor Day, Says Sees Global Chip Market Growing 9% Annually And Passing $1T In 2030; Sees AI Chips Making Up 40% Of Total Market In 2030 After Rapid Growth

Expands Arabic Content With New Series And Exclusive Concerts, Partners With UAE Telcos For 4K Streaming And Saudi Ministry Of Culture For Talent Development

AAPL

ANGH

Anghami Reports Strong 2024 Growth With 28% Increase In Video Streaming Engagement And 18% ARPU Rise; Launches AI-Driven Features, DolbyVision, And Apple Vision Pro App

Oppenheimer analyst Christopher Glynn maintains Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) with a Outperform and raises the price target from $260 to $305.

Oppenheimer Maintains Outperform on Applied Industrial Techs, Raises Price Target to $305

JD.com,&nbsp;Inc.&nbsp;(NASDAQ:&nbsp;JD) reported fiscal second-quarter 2024 revenue growth of 5.1%&nbsp;year over year&nbsp;to $37.11 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41964595/jd-com-announces-third-quarter-2024-results" rel="noreferrer noopener">analyst consensus estimate of $36.54 billion</a>.
JD posted&nbsp;an adjusted net income per ADS of $1.24, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.09</a>. The stock price slid after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41943966/stratasys-ceo-touts-turnaround-strong-market-gains-cost-cuts-drive-q3-beat-guidance-raised" rel="noreferrer noopener">Stratasys CEO Touts Turnaround: Strong Market Gains, Cost Cuts Drive Q3 Beat, Guidance Raised</a>
JD Segment Performance: JD.com's&nbsp;net product revenue increased by 4.8%&nbsp;year over year&nbsp;at $29.16 billion. Net service revenues rose 6.5%&nbsp;year over year&nbsp;to $7.95 billion.&nbsp;
JD Retail revenue climbed 6.1%&nbsp;year over year&nbsp;to $32.06 billion, Logistics revenue gained 6.6% year over year to $6.33 billion, and the new business revenues fell to $708 million.
JD.com's marketing expenses rose 25.7% to $1.4 billion in the quarter, forming 3.8% of revenues. The rise was mainly due to the increased spending in promotion activities.
Margin: Operating margin was 4.6% for the quarter, compared to 3.8% year over year. Adjusted operating margin improved 50 bps year over year to 5.0%. JD Retail's operating margin remained stable year over year at 5.2%.&nbsp;
Adjusted EBITDA increased 17.0% year over year to $2.1 billion, with a 5.8% margin.
JD.com used $1.97 billion in free cash flow for the quarter, used $0.89 billion in operating cash flow, and held $28.0 billion in cash and equivalents as of September-end.
JD.com's CEO, Sandy Xu, highlighted strong topline growth and solid profitability in the third quarter, driven by improved consumer sentiment. Xu attributed the performance to JD.com's robust supply chain and fulfillment infrastructure, which played a key role in China's trade-in program. The company saw significant growth in the general merchandise category, fueled by efforts to enhance user experience and positive responses to the Singles Day Grand Promotion.
CFO Ian Su Shan noted that JD.com's revenues grew 5.1% year-over-year, supported by a rebound in electronics and home appliance sales alongside consistent strength in general merchandise. The company's focus on enhancing supply chain capabilities led to improved gross and non-GAAP net margins.
JD.Com stock gained over 31% year-to-date.
Price Action: JD stock is up 1.65% at $36.28 in the premarket session&nbsp;at the last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41940062/tower-semiconductor-q3-earnings-revenue-and-profit-beat-plans-350-million-expansion" target="_blank" rel="noreferrer noopener">Tower Semiconductor Q3 Earnings: Revenue And Profit Beat, Plans $350 Million Expansion</a></li>
</ul>
Photo via Wikimedia Commons

Emerging Markets

JD.com Q3 Earnings: Revenue Beats Forecast Amid Consumer Rebound, Highlights Supply Chain Strength, Eyes Margin Growth

Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) with a Outperform and raises the price target from $26 to $28.

ATXS

Oppenheimer Maintains Outperform on Astria Therapeutics, Raises Price Target to $28

<a href="https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds" title="https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds">https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds</a>

Macro Economic Events

Commodities

Economics

Nigerian National Petroleum Company Limited Reaches 1.8M Barrels Per Day Of Oil Production

Sow Good (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 925 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $3.55 million which missed the analyst consensus estimate of $5.47 million by 35.02 percent. This is a 29.40 percent decrease over sales of $5.03 million the same period last year.

Earnings Misses

SOWG

Sow Good Q3 EPS $(0.33) Misses $(0.18) Estimate, Sales $3.55M Miss $5.47M Estimate

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Outperform and raises the price target from $63 to $65.

TARS

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $65

UBS analyst Christopher Schoell initiates coverage on Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy rating and announces Price Target of $102.

Comments

Litman Gregory Funds Trust Polen Capital Emerging Markets ex China Growth ETF

News

Latest news for Litman Gregory Funds Trust Polen Capital Emerging Markets ex China Growth ETF (ARCA:PCEM)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga